medigraphic.com
Colegio de Medicina Interna de México.

2025, Número 07

<< Anterior Siguiente >>

Med Int Mex 2025; 41 (07)


Papel terapéutico de los nucleótidos de citidina y uridina en la neuropatía diabética de pacientes con diabetes mellitus tipo 2: revisión de la evidencia

Carrasco TJG, Durán QJC, Majano CE, Gallo GM

Idioma: Español
Referencias bibliográficas: 72
Paginas: 402-417
Archivo PDF: 667.21 Kb.


RESUMEN

Antecedentes: La prevalencia de la diabetes mellitus ha aumentado de forma sustancial en las últimas décadas. Aunque existen múltiples tratamientos para la neuropatía diabética enfocados en la reducción de los síntomas, específicamente del dolor, hasta la fecha no hay recomendaciones que incluyan otros fármacos o complementos con efectos benéficos para la recuperación y reparación del nervio periférico.
Objetivo: Revisar la evidencia referente a la indicación de los nucleótidos de citidina y uridina en el tratamiento coadyuvante de pacientes con diabetes mellitus tipo 2 con neuropatía diabética.
Metodología: Búsqueda de artículos que evaluaron la toma de nucleótidos de citidina y uridina como parte del tratamiento de la neuropatía diabética en pacientes con diabetes mellitus tipo 2. Las bases de datos utilizadas para esta búsqueda fueron: PubMed, Scopus, Web of Science y ScienceDirect. El periodo abarca de 1970 a 2025 debido a que las primeras publicaciones de la evidencia fueron cercanas al decenio de 1980. Se utilizaron las palabras clave (MeSH): nucleótidos, citidina, uridina, bases nucleares, diabetes tipo 2, neuropatía.
Resultados: De 223 fuentes bibliográficas, se incluyeron 29 y eliminaron las que contenían información repetitiva, sin acceso, opiniones y cartas al editor.
Conclusiones: La indicación de nucleótidos debe considerarse solo en casos seleccionados y en el contexto de un tratamiento multimodal. Es evidente la necesidad de más estudios controlados para definir su eficacia, seguridad y perfiles de pacientes beneficiados.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jang HN, Oh TJ. Pharmacological and Nonpharmacologicaltreatments for painful diabetic peripheral neuropathy.Diabetes Metab J 2023; 47 (6): 743-756. https://doi.org.10.4093/dmj.2023.0018

  2. IDF diabetes atlas 2024. Diabetesatlas.org. https://diabetesatlas.org/atlas/tenth-edition/

  3. Savettieri G, Rocca WA, Salemi G, et al. Prevalence ofdiabetic neuropathy with somatic symptoms: a door-todoorsurvey in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology 1993; 43(6): 1115-1120. https://doi.org.10.1212/wnl.43.6.1115

  4. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by stagedseverity of various types of diabetic neuropathy, retinopathy,and nephropathy in a population-based cohort: theRochester Diabetic Neuropathy Study [published correctionappears in Neurology 1993; 43 (11): 2345. Neurology 1993;43 (4): 817-824. https://doi.org.10.1212/wnl.43.4.817

  5. Daousi C, Benbow SJ, Woodward A, MacFarlane IA. Thenatural history of chronic painful peripheral neuropathyin a community diabetes population. Diabet Med 2006;23 (9): 1021-1024. https://doi.org.10.1111/j.1464-5491.2006.01904.x

  6. Eid SA, Rumora AE, Beirowski B, et al. New perspectives indiabetic neuropathy. Neuron 2023; 111 (17): 2623-2641.https://doi.org.10.1016/j.neuron.2023.05.003

  7. International Association for the Study of Pain (IASP). InternationalAssociation for the Study of Pain; 2021. https://www.iasp-pain.org/resources/terminology/

  8. Hatch MN, Cushing TR, Carlson GD, Chang EY. Neuropathicpain and SCI: Identification and treatment strategies in the21st century. J Neurol Sci 2018; 384: 75-83. https://doi.org.10.1016/j.jns.2017.11.018

  9. Scholz J, Finnerup NB, Attal N, et al. The IASP classificationof chronic pain for ICD-11: chronic neuropathic pain.Pain 2019; 160 (1): 53-59. https://doi.org.10.1097/j.pain.0000000000001365

  10. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabeticneuropathy: mechanisms to management. PharmacolTher 2008; 120 (1): 1-34. https://doi.org.10.1016/j.pharmthera.2008.05.005

  11. Aziz N, Dash B, Wal P, Kumari P, Joshi P, Wal A. New horizonsin diabetic neuropathies: An updated review on theirpathology, diagnosis, mechanism, screening techniques,pharmacological, and future approaches. Curr DiabetesRev 2024; 20 (6): e201023222416. https://doi.org.10.2174/0115733998242299231011181615

  12. Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabeticneuropathy. Nat Rev Dis Primers 2019; 5 (1): 41. https://doi.org.10.1038/s41572-019-0092-1

  13. Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosisand clinical management of diabetic sensorimotor peripheralneuropathy. Nat Rev Endocrinol 2021; 17 (7): 400-420.https://doi.org.10.1038/s41574-021-00496-z

  14. Rumora AE, Kim B, Feldman EL. A Role for fatty acids inperipheral neuropathy associated with type 2 diabetes andprediabetes. Antioxid Redox Signal 2022; 37 (7-9): 560-577.https://doi.org.10.1089/ars.2021.0155

  15. Wiggin TD, Sullivan KA, Pop-Busui R, et al. Elevated triglyceridescorrelate with progression of diabetic neuropathy.Diabetes 2009; 58 (7): 1634-1640. https://doi.org.10.2337/db08-1771

  16. Erbas T, Ertas M, Yucel A, Keskinaslan A, Senocak M;TURNEP Study Group. Prevalence of peripheral neuropathyand painful peripheral neuropathy in Turkish diabeticpatients. J Clin Neurophysiol 2011; 28 (1): 51-55. https://doi.org.10.1097/WNP.0b013e3182051334

  17. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ.Hypertension as a risk factor for diabetic neuropathy: aprospective study. Diabetes 1997; 46 (4): 665-670. https://doi.org.10.2337/diab.46.4.665

  18. Meisinger C, Döring A, Thorand B, Heier M, Löwel H. Body fatdistribution and risk of type 2 diabetes in the general population:are there differences between men and women? TheMONICA/KORA Augsburg cohort study. Am J Clin Nutr 2006;84 (3): 483-489. https://doi.org.10.1093/ajcn/84.3.483

  19. Miralles-García JM, de Pablos-Velasco P, Cabrerizo L, PérezM, López-Gómez V; Sociedad Española de Endocrinologíay Nutrición. Prevalence of distal diabetic polyneuropathyusing quantitative sensory methods in a population withdiabetes of more than 10 years’ disease duration. EndocrinolNutr 2010; 57 (9): 414-420. https://doi.org.10.1016/j.endonu.2010.05.006

  20. Hébert HL, Veluchamy A, Torrance N, Smith BH.Risk factors for neuropathic pain in diabetes mellitus.Pain. 2017;158(4):560-568. doi:10.1097/j.pain.0000000000000785.

  21. Price R, Smith D, Franklin G, et al. Oral and TopicalTreatment of Painful Diabetic Polyneuropathy: PracticeGuideline Update Summary: Report of the AAN GuidelineSubcommittee. Neurology. 2022;98(1):31-43. doi:10.1212/WNL.0000000000013038

  22. Azmi S, Alam U, Burgess J, Malik RA. State-of-the-artpharmacotherapy for diabetic neuropathy. Expert OpinPharmacother. 2021;22(1):55-68. doi:10.1080/14656566.2020.1812578

  23. D'Souza RS, Barman R, Joseph A, Abd-Elsayed A. Evidencebasedtreatment of painful diabetic neuropathy: A systematicreview. Curr Pain Headache Rep 2022; 26 (8): 583-594.https://doi.org.10.1007/s11916-022-01061-7

  24. Mu A, Weinberg E, Moulin DE, Clarke H. Pharmacologicmanagement of chronic neuropathic pain: Review of theCanadian Pain Society consensus statement. Can FamPhysician 2017; 63 (11): 844-852.

  25. Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapyfor diabetic peripheral neuropathy pain and quality oflife: A systematic review [published correction appearsin Neurology 2017; 89 (8): 875. https://doi.org.10.1212/WNL.0000000000004323]. Neurology 2017; 88 (20): 1958-1967. https://doi.org.10.1212/WNL.0000000000003882

  26. Jang HN, Oh TJ. Pharmacological and nonpharmacologicaltreatments for painful diabetic peripheral neuropathy.Diabetes Metab J 2023; 47 (6): 743-756. https://doi.org.10.4093/dmj.2023.0018

  27. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin forthe symptomatic treatment of painful neuropathy in patientswith diabetes mellitus: a randomized controlled trial.JAMA 1998; 280 (21): 1831-1836. https://doi.org.10.1001/jama.280.21.1831

  28. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vsamitriptyline in painful diabetic neuropathy: an open-labelpilot study. J Pain Symptom Manag 2000; 20 (4): 280-285.https://doi.org.10.1016/s0885-3924(00)00181-0

  29. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy:A Position Statement by the American DiabetesAssociation. Diabetes Care 2017; 40 (1): 136-154. https://doi.org.10.2337/dc16-2042

  30. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U.Pregabalin for the treatment of painful diabetic peripheralneuropathy: a double-blind, placebo-controlled trial.Pain 2004; 110 (3): 628-638. https://doi.org.10.1016/j.pain.2004.05.001

  31. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relievessymptoms of painful diabetic neuropathy: a randomizedcontrolled trial. Neurology 2004; 63 (11): 2104-2110.https://doi.org.10.1212/01.wnl.0000145767.36287.a1

  32. Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis ofduloxetine vs. pregabalin and gabapentin in the treatmentof diabetic peripheral neuropathic pain. BMC Neurol 2009;9: 6. https://doi.org.10.1186/1471-2377-9-6

  33. Bates D, Schultheis BC, Hanes MC, et al. A Comprehensivealgorithm for management of neuropathic pain [publishedcorrection appears in Pain Med 2023; 24 (2): 219. https://doi.org.10.1093/pm/pnac194]. Pain Med 2019; 20 (Suppl1): S2-S12. https://doi.org.10.1093/pm/pnz075

  34. Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologicinterventions for painful diabetic neuropathy:An umbrella systematic review and comparative effectivenessnetwork meta-analysis [published correctionappears in Ann Intern Med 2015; 162 (8): 600. https://doi.org.10.7326/L15-0078-3] [published correction appearsin Ann Intern Med 2015; 162 (10): 739. https://doi.org.10.7326/L15-5096]. Ann Intern Med 2014; 161 (9):639-649. https://doi.org.10.7326/M14-0511

  35. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extendedrelease in the treatment of painful diabetic neuropathy:a double-blind, placebo-controlled study [published correctionappears in Pain 2005; 113 (1-2): 248]. Pain 2004; 110(3): 697-706. https://doi.org.10.1016/j.pain.2004.05.010

  36. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versusimipramine in painful polyneuropathy: a randomized, controlledtrial. Neurology 2003; 60 (8): 1284-1289. https://doi.org.10.1212/01.wnl.0000058749.49264.bd

  37. Razazian N, Baziyar M, Moradian N, et al. Evaluation ofthe efficacy and safety of pregabalin, venlafaxine, andcarbamazepine in patients with painful diabetic peripheralneuropathy. A randomized, double-blind trial. Neurosciences(Riyadh) 2014; 19 (3): 192-198.

  38. Majdinasab N, Kaveyani H, Azizi M. A comparative doubleblindrandomized study on the effectiveness of Duloxetineand Gabapentin on painful diabetic peripheral polyneuropathy.Drug Des Devel Ther 2019; 13: 1985-1992. https://doi.org.10.2147/DDDT.S185995

  39. Rakusa M, Marolt I, Stevic Z, Rebrina SV, et al. Efficacy ofpregabalin and duloxetine in patients with painful diabeticperipheral neuropathy (PDPN): A multi-centre phase IVclinical trial-BLOSSOM. Pharmaceuticals (Basel) 2023; 16(7): 1017. https://doi.org.10.3390/ph16071017

  40. Didangelos T, Karlafti E, Kotzakioulafi E, et al. Vitamin B12supplementation in diabetic neuropathy: A 1-year, randomized,double-blind, placebo-controlled trial. Nutrients 2021;13 (2): 395. https://doi.org.10.3390/nu13020395

  41. Karaganis S, Song XJ. B vitamins as a treatment for diabeticpain and neuropathy. J Clin Pharm Ther 2021; 46 (5): 1199-1212. https://doi.org.10.1111/jcpt.13375

  42. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology,symptoms, mechanisms, and management. Lancet 1999;353 (9168): 1959-1964. https://doi.org.10.1016/S0140-6736(99)01307-0

  43. Serra JP, Veciana MG, Bordas LB. Therapeutic effects of anassociation of CMP, UTP, and vitamin B12 in fifty cases ofperipheral neuropathies. N Engl J Med 1972; VI (64): 1-7.

  44. Lauretti GC, Omals M, Pereira AC, et al. Clinical evaluationof the analgesic effect of the cytidine-uridine-hydroxocobalamincomplex as a coadjuvant in the treatment ofchronic neuropathic low back pain. Column 2004; 3 (2):73-6.

  45. National Human Genome Research Institute. Genome.gov.https://www.genome.gov/es/genetics-glossary

  46. Baer HP, Drummond GI. Physiological and regulatoryfunctions of adenosine and adenine nucleotides. 1979.Raven Press.

  47. Corriden R, Insel PA. New insights regarding the regulationof chemotaxis by nucleotides, adenosine, and theirreceptors. Purinergic Signal 2012; 8 (3): 587-598. https://doi.org.10.1007/s11302-012-9311-x

  48. Fausther M, Sévigny J. Extracellular nucleosides andnucleotides regulate liver functions via a complex systemof membrane proteins. C R Biol 2011; 334 (2): 100-117.https://doi.org.10.1016/j.crvi.2010.12.005

  49. Zimmermann H. Extracellular ATP and other nucleotidesubiquitoustriggers of intercellular messenger release. PurinergicSignal 2016; 12 (1): 25-57. https://doi.org.10.1007/s11302-015-9483-2

  50. Burnstock G. Pathophysiology and therapeutic potentialof purinergic signaling. Pharmacol Rev 2006; 58 (1): 58-86.https://doi.org.10.1124/pr.58.1.5

  51. Jacobson KA, Paoletta S, Katritch V, et al. Nucleotides actingat P2Y receptors: Connecting structure and function. MolPharmacol 2015; 88 (2): 220-230. https://doi.org.10.1124/mol.114.095711

  52. Burnstock G. Purine and pyrimidine receptors. Cell MolLife Sci 2007; 64 (12): 1471-1483. https://doi.org.10.1007/s00018-007-6497-0

  53. Mamedova LK, Gao ZG, Jacobson KA. Regulation of deathand survival in astrocytes by ADP activating P2Y1 and P2Y12receptors. Biochem Pharmacol 2006; 72 (8): 1031-1041.https://doi.org.10.1016/j.bcp.2006.07.017

  54. Ulrich H, Abbracchio MP, Burnstock G. Extrinsic purinergicregulation of neural stem/progenitor cells: implications forCNS development and repair. Stem Cell Rev Rep 2012; 8(3): 755-767. https://doi.org.10.1007/s12015-012-9372-9

  55. Neary JT, Zimmermann H. Trophic functions of nucleotidesin the central nervous system. Trends Neurosci 2009; 32(4): 189-198. https://doi.org.10.1016/j.tins.2009.01.002

  56. Zimmermann H, Braun N. Extracellular metabolism ofnucleotides in the nervous system. J Autonomic Pharmacol1996; 16 (6): 397-400.

  57. Jacobson KA, Boeynaems JM. P2Y nucleotide receptors:promise of therapeutic applications. Drug Discovery Today2010; 15 (13): 570-8.

  58. Ipata PL. Origin, utilization, and recycling of nucleosidesin the central nervous system. Adv Physiol Educ 2011; 35(4): 342-346. https://doi.org.10.1152/advan.00068.2011

  59. Inoue K. The function of microglia through purinergic receptors:neuropathic pain and cytokine release. PharmacolTher 2006; 109 (1-2): 210-226. https://doi.org.10.1016/j.pharmthera.2005.07.001

  60. Kobayashi D, Ohkubo S, Nakahata N. Contribution ofextracellular signal-regulated kinase to UTP-induced interleukin-6 biosynthesis in HaCaT keratinocytes. J PharmacolSci 2006; 102 (4): 368-376. https://doi.org.10.1254/jphs.fp0060669

  61. Zhang Z, Wang Z, Ren H, et al. P2Y(6) agonist uridine5'-diphosphate promotes host defense against bacterialinfection via monocyte chemoattractant protein-1-mediatedmonocytes/macrophages recruitment. J Immunol2011; 186 (9): 5376-5387. https://doi.org.10.4049/jimmunol.1002946

  62. Stoll G, Jander S, Myers RR. Degeneration and regenerationof the peripheral nervous system: from Augustus Waller’sobservations to neuroinflammation. J Peripher NervSyst 2002; 7 (1): 13-27. https://doi.org.10.1046/j.1529-8027.2002.02002.x

  63. Boucher I, Kehasse A, Marcincin M, et al. Distinct activationof epidermal growth factor receptor by UTP contributesto epithelial cell wound repair. Am J Pathol 2011; 178 (3):1092-1105. https://doi.org.10.1016/j.ajpath.2010.11.060

  64. Martiáñez T, Lamarca A, Casals N, Gella A. N-cadherinexpression is regulated by UTP in schwannoma cells. PurinergicSignal 2013; 9 (2): 259-270. https://doi.org.10.1007/s11302-012-9348-x

  65. Aslan E, Kocaeli H, Bekar A, et al. CDP-choline and its endogenousmetabolites, cytidine and choline, promote thenerve regeneration and improve the functional recoveryof injured rat sciatic nerves. Neurol Res 2011; 33 (7): 766-773. https://doi.org.10.1179/1743132811Y.0000000004

  66. Caner B, Kafa MI, Bekar A, et al. Intraperitoneal administrationof CDP-choline or a combination of cytidineplus choline improves nerve regeneration and functionalrecovery in a rat model of sciatic nerve injury. Neurol Res2012; 34 (3): 238-245. https://doi.org.10.1179/1743132812Y.0000000003

  67. Durany N. Effect of the drug Nucleo CMP Forte in nervecell regeneration. Parkins Related Dis 2005; 11 (2): 214-42.

  68. Gallai V, Mazzotta G, Montesi S, et al. Effects of uridine inthe treatment of diabetic neuropathy: an electrophysiologicalstudy. Acta Neurol Scand 1992; 86 (1): 3-7. https://doi.org.10.1111/j.1600-0404.1992.tb08045.x

  69. Bouna Seck L, Basse A, Hachim Cissé E, et al. Efficacy andtolerance of combination of Cytidine 5’ monophosphate(CMP) and uridine-5’ triphosphate trisodium (UTP) inpatients with diabetic neuropathy: results of a studyconducted in Dakar-Senegal. Int J Med Med Sci 2015; 5(8): 284-287.

  70. Covarrubias-Gómez A, Guevara-López UM, Cantú-Brito C,et al. Recomendaciones de práctica clínica para el manejodel dolor neuropático: Grupo de interés en dolor neuropáticode la Asociación Mexicana para el Estudio y Tratamientodel Dolor. Rev Mex Anest 2015; 38 (4): 264-276.

  71. Gella A, Martiañez T, Lamarca A, et al. Un fármaco basadoen nucleótidos protege contra la neurotoxicidad inducidapor glutamato y MPP+. Neurociencia Med 2011; 2: 154-160. https://doi.org.10.4236/nm.2011.22022

  72. Hedding-Eckerich M. Treatment of peripheral nerve damagewith pyrimidine nucleotides Results of a retrospectiveanalysis of data on more than 2,000 outpatient cases. DerAllgemeinarzt 2001.




2020     |     www.medigraphic.com